Spectral MD Holdings, Ltd. Exercise of Options (4539K)

TIDMSMD

RNS Number : 4539K

Spectral MD Holdings, Ltd.

25 August 2023

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

Exercise of Options

LONDON, U.K. AND DALLAS, TX, U.S. -Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces the exercise of options (the "Exercise") by certain employees of the Company including the Company's CEO, Wensheng Fan (together the "Employees") as detailed below.

The Employees have exercised options over an aggregate of 1,155,159 shares of common stock of US$0.001 each in the Company ("Common Stock").

796,587 shares of Common Stock have been issued and allotted pursuant to the Company's 2018 Long-Term Incentive Plan. As previously announced on 7 November 2022, up to 2 million shares of Common Stock under the 2018 Long-Term Incentive Plan were previously admitted to trading on AIM pursuant to a block listing application. A further 358,572 shares of Common Stock have been issued and allotted pursuant to the Company's Investor Options, as detailed below.

Director/PDMR Shareholding

Pursuant to the Exercise, Wensheng Fan, Chief Executive Officer, has exercised options over 358,572 shares of Common Stock at an exercise price of US$0.20 per share of Common Stock.

As a result, Wensheng Fan's beneficial interest in the Company is 1,858,572 shares of Common Stock, representing approximately 1.35% of the total issued share capital.

Admission and Total Voting Rights

The Company will apply for 358,572 shares of Common Stock to be admitted to trading on AIM, with admission expected to take place at 8:00 a.m. on or around 31 August 2023 ("Admission"). The shares of Common Stock will rank pari passu in all respects with existing Common Stock. A further 796,587 shares of Common Stock were previously admitted to trading pursuant to a block listing.

Following Admission, there will be 137,404,723 ordinary shares of Common Stock of US $0.001 each in issue, with one voting right per share of Common Stock. The total number of voting rights in the Company will therefore be 137,404,723.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company under the Company's Certificate of Incorporation. No Common Stock is held in treasury.

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

For further information please contact:

 
 Spectral MD Holdings, Ltd.                                                         [e-mail] 
 Wensheng Fan, Chief Executive Officer                                                via Walbrook PR 
  Nils Windler, Chief Financial Officer 
 
 SP Angel Corporate Finance LLP (NOMAD and Joint Broker for Spectral MD)     Tel: [phone] 
 Stuart Gledhill / Harry Davies-Ball (Corporate Finance) 
  Vadim Alexandre / Rob Rees (Sales & Broking) 
 
 The Equity Group Inc. (US Investor Relations)                                 [e-mail] 
 Devin Sullivan                                                                     Tel: [phone] 
 
 Walbrook PR Ltd (UK Media & Investor Relations)                            [e-mail] 
 Paul McManus / Louis Ashe-Jepson / Alice Woodings                           Tel: [phone] 
 
 

About Spectral MD

Spectral MD is a predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care for burn, DFU, and future clinical applications. At Spectral MD, we are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown"(R) with our DeepView(R) Wound Diagnostics System. The Company's DeepView(R) platform is the only predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results that substantially exceed the current standard of care, Spectral MD's diagnostic platform is expected to provide faster and more accurate treatment insight, significantly improving patient care and clinical outcomes. For more information, visit the Company at: www.spectralmd.com.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                           Wensheng Fan 
     -----------------------------  ------------------------------------ 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                CEO 
     -----------------------------  ------------------------------------ 
 b)   Initial                        Initial notification 
       notification/Amendment 
     -----------------------------  ------------------------------------ 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                           Spectral MD Holdings, Ltd 
     -----------------------------  ------------------------------------ 
 b)   LEI                            213800VXW1FVGWTCKL44 
     -----------------------------  ------------------------------------ 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description                    Common Stock of US$0.001 each 
       of the Financial 
       instrument, 
       type of 
       instrument 
      Identification                 USU8457V1099 
       code 
     -----------------------------  ------------------------------------ 
 b)   Nature of                      Exercise of Options 
       the transaction 
     -----------------------------  ------------------------------------ 
 c)   Price(s)                         Price(s)      Volume(s) 
       and volume(s)                    1. US$0.20    358,572 
                                                     ---------- 
     -----------------------------  ------------------------------------ 
 d)   Aggregated                       Price(s)    Volume(s) 
       information:                     US$0.20     358,572 
       - Aggregated                                ---------- 
       volume 
       - Price 
     -----------------------------  ------------------------------------ 
 e)   Date of                        18 August 2023 
       the transaction 
     -----------------------------  ------------------------------------ 
 f)   Place of                       Outside a trading venue 
       the transaction 
     -----------------------------  ------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEASPSALPDEEA

(END) Dow Jones Newswires

August 25, 2023 02:00 ET (06:00 GMT)